Kornimate/medical-research-clean huggingface dataset:
a quality of life intervention for young african american breast cancer survivors in treatment

Conditions: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8

Summary: this clinical trial studies the use of a quality of life intervention called y-ambient to help young african american with stage i-iii breast cancer manage daily life. y-ambient is a four-month, telephone-based intervention that includes three themed education sessions with three follow-up sessions, written materials, and videos. the y-ambient intervention may improve quality of life and other health-related outcomes in young african american breast cancer survivors.

primary objectives: i. evaluate feasibility and acceptability of y-ambient and enhanced usual care among young african american breast cancer survivors. ii. explore the degree to which the y-ambient versus (vs.) enhanced usual care affects preliminary health-related outcomes among young african american (aa survivors). outline: patients are randomized to 1 of 2 arms. arm i (y-ambient): patients receive three themed education sessions over 1 hour each, written materials, and videos at month 1. patients also participate in 3, 20 minutes telephone reinforcement calls to discuss how they are doing and discuss any concerns that they are still managing at months 2, 3, and 4. arm ii (enhanced usual care): patients receive usual care at month 1. patients also participate in 3, 20 minutes telephone reinforcement calls to discuss their chemotherapy regimen at months 2, 3, and 4. after completion of study, patients are followed up at 1 month.

Eligibility criteria:
inclusion criteria: * biologically born women * self-identify as aa * are aged 18 to 44 years on study entry * are diagnosed with breast cancer stage i-iii * are in treatment with chemotherapy and/or radiation for stage i-iii breast cancer at study entry * are english- speaking * have telephone and internet access exclusion criteria: * participation in formal survivorship navigation programs because they are associated with improved health- related outcomes, which could be a confounder
a study to evaluate the safety and immunogenicity of gsk biologicals' seasonal influenza vaccine in children

Conditions: Influenza

Summary: this study is designed to test the immunogenicity and safety of an investigational influenza vaccine, in children compared to two other influenza vaccines.


Eligibility criteria:
inclusion criteria: * subjects who the investigator believes that they and/or their parent(s) or legally acceptable representative(s) can and will comply with the requirements of the protocol. * a male or female child aged between 6 months and 17 years inclusive at the time of the first vaccination; children are eligible regardless of history of administration of influenza vaccine in a previous season. * written informed consent obtained from the subject/from the parent(s)/legally acceptable representative(s) of the subject. * written informed assent obtained from the subject if/as required by local regulations. * subjects in stable health as determined by investigator's clinical examination and assessment of subjects' medical history. * female subjects of non-childbearing potential may be enrolled in the study. * female subjects of childbearing potential may be enrolled in the study, if the subject * has practiced adequate contraception for 30 days prior to vaccination, and * has a negative pregnancy urine test on the day of vaccination, and * has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series. exclusion criteria: * child in care * use of any investigational or non-registered product other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.prior receipt of any seasonal or pandemic influenza vaccine within 6 months preceding the first dose of study vaccine, or planned use during the study period. * chronic administration of immunosuppressants or other immune modifying drugs within six months prior to the first vaccine dose. * administration of immunoglobulins and/or any blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period. * history of guillain-barré syndrome within 6 weeks of receipt of prior influenza vaccine. * any known or suspected allergy to any constituent of influenza vaccines; a history of anaphylactic-type reaction to consumption of eggs; or a history of severe adverse reaction to a previous influenza vaccine. * fever at the time of enrolment. * acute disease at the time of enrolment. * any significant disorder of coagulation or treatment with coumadin derivatives or heparin. * pregnant or lactating female. * female planning to become pregnant or planning to discontinue contraceptive precautions. * any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. * ongoing aspirin therapy. * any other condition which, in the opinion of the investigator, prevents the subject from participating in the study.

Keywords: influenza
default genetics referrals for young-onset colorectal cancer

Conditions: Colorectal Cancer

Summary: the investigators will perform a pilot implementation study of a default genetics referral process among patients with young-onset crc diagnosed between ages 40 and 49.

the incidence of young-onset colorectal cancer (crc) - defined as a diagnosis of crc prior to age 50 - has increased at alarming rates in recent years. over 75% of cases occur in patients diagnosed between 40-49 years old, a group that is not traditionally included in young adult cancer initiatives tailored only to patients up to 39 years of age. young age of crc onset is a defining feature of hereditary crc syndromes; as such, the national comprehensive cancer network and american college of medical genetics and genomics recommend germline genetics evaluations for all patients diagnosed with crc under the age of 50. however, multiple studies have shown suboptimal rates and racial and socioeconomic disparities in guideline-recommended genetics evaluations. in this pilot implementation study, the investigators aim to develop, implement, and evaluate the effects of a default genetics referral process among patients with young-onset crc diagnosed between 40-49 years old. the investigators hypothesize that by applying defaults, or pre-selected choices, to minimize the cognitive effort that patients and clinicians use to make decisions, default referrals will improve rates of genetics referrals while reducing existing racial and socioeconomic disparities. the investigators will implement this intervention at five academic and community hospitals within penn medicine that serve a racially, socioeconomically, and geographically diverse patient population. the investigators will use an automated electronic health record-based algorithm to identify eligible patients, after which default referrals for genetic risk evaluation will be made unless patients or their oncology clinicians opt out. the investigators will rigorously evaluate the impact of this default genetics referral process using mixed methods leveraging models and frameworks from the field of implementation science.

Eligibility criteria:
inclusion criteria: * newly diagnosed with colon or rectal adenocarcinoma * between 40-49 years old at the time of index cancer diagnosis * at least two visits at penn medicine for the evaluation or treatment of the index cancer exclusion criteria: * diagnosis of in situ cancer * known genetic predisposition to cancer * genetic testing after index cancer diagnosis
effect of acupuncture on hemodynamics and pain of post craniotomy patients with mechanical ventilation

Conditions: Post Craniotomy

Summary: the aim of this clinical trial is to prove that acupuncture therapy combined with standard therapy can optimize hemodynamics and reduce pain in post-craniotomy patients with mechanical ventilation. the main questions it aims to answer are: * is there a difference in mean arterial pressure, pulse rate, respiratory rate, oxygen fraction and pain in the acupuncture therapy group combined with standard therapy compared to standard therapy after the 3rd therapy and compared to before therapy? * is there a difference in changes in ventilator mode in the acupuncture therapy group combined with standard therapy compared to standard therapy after the 3rd therapy? * are there any side effects in the acupuncture therapy group combined with standard therapy? researchers will compare acupuncture therapy combined with standard therapy to standard therapy only participants will: * receive acupuncture therapy for 3 consecutive days * outcomes will be assessed after 3 days of therapy.


Eligibility criteria:
inclusion criteria: * male or female over 18 years old * subjects who received craniotomy with vascular etiology * conscious patients with gcs over 9 before craniotomy * using simv mode mechanical ventilation * family willing for the patient to participate in the study until completion and signed informed consent exclusion criteria: * history of neuromusculoskeletal diseases such as myasthenia gravis or multiple sclerosis * treatment for lung cancer and covid-19 * there is infection, scarring or malignancy in the acupuncture stabbing area * patients with blood clotting disorders, platelets under 50. 000/µl, patients on anticoagulant therapy with inr over 2.0
the effect of statin treatment on trained innate immunity

Conditions: Atherosclerosis

Summary: the innate immune system plays a pivotal role in the development and progression of atherosclerosis. recently, it was reported that monocytes can develop a long-lasting immunological memory after stimulation with various microorganisms, which has been termed 'trained innate immunity'. this memory is induced by epigenetic reprogramming, in particular trimethylation of lysine 4 at histone 3 (h3k4me3). in this study, the investigators aim to investigate the immunophenotype of circulating monocytes in patients with elevated ldl cholesterol levels and the effect of statins on this phenotype.

the innate immune system plays a pivotal role in the development and progression of atherosclerosis. recently, it was reported that monocytes can develop a long-lasting immunological memory after stimulation with various microorganisms, which has been termed 'trained innate immunity'. this memory is induced by epigenetic reprogramming, in particular trimethylation of lysine 4 at histone 3 (h3k4me3). the main objective is to study whether circulating monocytes of patients with elevated levels of ldl have a phenotype of trained innate immunity compared to control patients. subsequently the investigators will study the effect of treatment with statins on the increased inflammatory response and epigenetic changes of the innate immune system.

Eligibility criteria:
inclusion criteria: * aged 18 years or older * elevated ldl levels (\>4.9 mmol/l) * decision made by treating physician to initiate statin treatment exclusion criteria: * previous cardiovascular events.
comparison of bleeding risk between rivaroxaban and apixaban: the pilot study

Conditions: Venous Thromboembolism

Summary: this vanguard pilot study compares rivaroxaban and apixaban, two of the new oral blood thinners for the treatment of blood clots. half of the patients will receive apixaban and half will receive rivaroxaban. the main objective is to determine the feasibility of patient recruitment and resources required to follow enrolled patients and inform for a larger, multi-centered trial and to assess which one is safer.

recently developed new oral anticoagulants (oac) overcome some of the limitations of established therapy with vitamin k antagonists (vka) and low molecular weight heparin (lmwh) for treatment of acute venous thromboembolism (vte), due to ease of administration and more predictable pharmacokinetic properties. many clinical questions about the new oac remain unanswered because there have not been direct head-to-head comparison trials. for example, although studies have shown that rivaroxaban and apixaban are at least as effective and safe as lmwh and vka, meta-analyses suggest that apixaban may be associated with lower bleeding risk. concerns about the potential impact of medication non-adherence have been raised. compliance with twice daily medications (e.g. apixaban) is often worse than once daily medications (e.g. rivaroxaban). both of these medications are approved by health canada for treatment of vte yet there is genuine uncertainty about which of the two direct oac confer the best risk-to-benefit ratio.this is a multi-centre, prospective randomized open blinded end-point (probe) trial assessing clinical feasibility for a larger multi-centered trial comparing bleeding outcomes using apixaban vs. rivaroxaban for treatment of acute vte. the primary objective of the study is to determine if it is feasible to conduct a large randomized multicenter trial comparing apixaban vs. rivaroxaban for the treatment of acute vte. the secondary objectives are to assess safety and superiority of apixaban vs rivaroxaban.

Eligibility criteria:
inclusion criteria: * confirmed newly diagnosed acute vte (proximal lower extremity deep vein thrombosis and segmental or greater pulmonary embolism) * age ≥ 18 years old * written informed consent exclusion criteria: * any contraindication for anticoagulation such as active bleeding * clinically significant liver disease or alanine aminotransferase (alt) levels ≥ 3 times the upper limit of normal range * creatinine clearance \< 30 ml/min calculated with the cockcroft-gault formula (29) * known allergies to either apixaban or rivaroxaban * pregnancy * use of contraindicated medications with apixaban or rivaroxaban * active malignancy in the last 6 months (excluding localized skin malignancy) * no private insurance coverage for the study drug or not willing to pay for study drug
free venlafaxine treatment for marijuana addiction and depression - 1

Conditions: Depression; Marijuana Abuse

Summary: the purpose of this study is to determine if venlafaxine extended release (ven-xr) is effective in treating individuals with marijuana addiction and depression.

given that depression and marijuana addiction often occur together, medications to treat individuals diagnosed with both conditions may be effective. the purpose of this study is to determine the effectiveness of ven-xr in treating individuals diagnosed with depression and marijuana addiction. during this twelve-week, double-blind, placebo-controlled study, study visits will occur twice each week. during study visits, participants will receive either placebo or medication and provide a urine sample for drug screening. blood tests will be collected each month and women must take pregnancy tests each month. throughout the study, all participants will receive individualized psychotherapy sessions. at each study visit, participants will be given $5 to cover transportation costs.

Eligibility criteria:
inclusion criteria: * meets criteria for current marijuana addiction and reports marijuana as primary drug of abuse * currently meets criteria for major depression or dysthymic disorder and receive a score of greater than or equal to 12 on the hamilton depression inventory * clinically depressed for at least 3 months during a period of active marijuana use * women of child-bearing age will be included provided that they are not pregnant, based on the results of a blood pregnancy done at the time of screening and agree to use a method of contraception with proven efficacy and not to become pregnant during the study. to confirm this, blood pregnancy tests will be repeated monthly. women will be provided a full explanation of the potential dangers of pregnancy while on the study. if a woman becomes pregnant, the study medication will be discontinued. exclusion criteria: * meets criteria for past manic or psychotic disorder, unless substance-related * history of a seizure disorder * individuals with chronic organic mental syndrome * any significant risk for suicide based on current assessment and history of attempts * history of allergic reaction to either venlafaxine or ven-xr * unstable physical disorders that might make participation hazardous, such as uncontrolled hypertension and tachycardia (sbp\>150, dbp \>90, or a sitting quietly hr\>100), acute hepatitis (patients with chronic mildly elevated transaminase levels (\<2x upper limit of normal are acceptable) or unstable diabetes * history of failure to respond to a previous adequate trial of venlafaxine of at least 300 mg. for at least a 6-week period * physical dependence on any other drugs (excluding nicotine) that would require medical detoxification * currently being prescribed psychotropic medication by another physician (in the last 3 weeks), except for acute treatment of insomnia. * pregnant or breast-feeding

Keywords: cannabis dependence depression treatment venlafaxine
analgesic effect of an injection of botulinum toxin type a in the ganglion impar in patients with chronic proctalgia

Conditions: Proctalgia

Summary: the main objective is to evaluate the analgesic efficacy of botulinum toxin type a in refractory chronic proctalgia one month after a bilateral injection of 50 units of botox ® in the ganglion impar (total dose = 100 units)


Eligibility criteria:
inclusion criteria: * age \> 18 years * patient with chronic proctalgia according to the criteria of rome iii * chronic or recurrent rectal pain * pains evolve over periods of at least 20 minutes * with the exclusion of other causes of rectal pain: ischemic, inflammatory bowel disease, cryptic lesions, intramuscular abscess, anal fissure, hemorrhoids, prostatitis and isolated coccydynia * pains evolve in a regular way since more than 3 months and the symptoms started since at least 6 months * these chronic proctalgia include syndromes of anus elevator and nonspecific functional anorectal pains * patient with positive anesthetic block of ganglion impar (minimum of 30 days before d0 and maximum of 270 days before d0) * main score (sp) ≥ 4 before infiltration of botulinum toxin type a * signed informed consent * subjects affiliated with an appropriate social security system exclusion criteria: * pain related malignancy * patients with bleeding risk and recent anticoagulant therapy * surgery within 3 months * pre-existing anal incontinence * intolerance of botulinum toxin a, local anesthetics and radio contrast medium * injection of botulinum toxin in any place whatsoever in the previous 3 months * pregnancy and breast feeding * antibiotic treatment by aminoglycosides * recent anti-inflammatory treatment * severe myasthenia * lambert-eaton syndrome * patients with neurological disorders, dysphagia, food choking or inhalation pneumonia

Keywords: chronic proctalgia botulinum toxin type a ganglion impar perineal pain pudendal neuralgia refractory chronic proctalgia
ctdna dynamic monitoring and its role of prognosis in stage i nscls by ngs

Conditions: Non-small Cell Lung Cancer Stage I

Summary: ctdna detection is a noninvasive detection method, and the second generation of high-throughput gene sequencing (ngs) is an important means of detecting ctdna, which can detect trace ctdna from smaller plasma samples. this project is to study the role of ctdna dynamic monitoring of stage i nsclc by ngs technique to verify the prognostic predictive effect of ctdna .

ctdna detection as a noninvasive detection method, can truly reflect the real tumor tissue gene mutation map and frequency, is the evaluation of therapeutic effect and the important monitoring indicators of clinical follow-up after treatment. the second generation of high-throughput gene sequencing (ngs) is an important means of detecting ctdna, which can detect trace ctdna from smaller plasma samples. the ctdna dynamic monitoring of stage i non-small cell lung cancer (nsclc) was performed by the second generation gene sequencing (ngs) technique to verify the prognostic predictive effect of ctdna in stage i nsclc patients without radiotherapy and targeted therapy.

Eligibility criteria:
inclusion criteria: * postoperative histopathological diagnosis of tnm stage ia / ib nsclc with r0 resection; * no adjuvant chemotherapy, radiotherapy, targeted drug therapy or biotherapy after surgery; general selection criteria: * men or women of age ≥18 years and \<75 years old; * ecog behavior status score 0 to 1; exclusion criteria: * patients with other cancers other than nsclc within five years prior to this study; * who can not get enough tumor histological specimens (non-cytological) for analysis; * human immunodeficiency virus (hiv) infection; * nsclc mixed with patients with small cell lung cancer; * pregnant or lactating women; * there is a clear history of neurological or mental disorders, including epilepsy or dementia; * conditions that investigators think is not suitable for inclusion.

Keywords: nsclc stage i the next generation of high-throughput gene sequencing (ngs) ctdna